{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T15:14:01Z","timestamp":1781968441975,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejim.2023.07.010","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T15:49:41Z","timestamp":1689263381000},"page":"98-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Prevalence of anti-synthetase antibodies among systemic sclerosis patients"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6363-5981","authenticated-orcid":false,"given":"Wakar","family":"Garra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2023.07.010_bib0001","first-page":"1","article-title":"Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need","author":"Herrick","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ejim.2023.07.010_bib0002","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and survival in systemic sclerosis: systematic review and meta-analysis","volume":"44","author":"Rubio-Rivas","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ejim.2023.07.010_bib0003","first-page":"14","article-title":"Scleroderma overlap syndrome","volume":"13","author":"Balbir-Gurman","year":"2011","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.ejim.2023.07.010_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2020.06.021","article-title":"Extended myositis-specific and -associated antibodies profile in systemic sclerosis: a cross-sectional study","volume":"88","author":"Leurs","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ejim.2023.07.010_bib0005","first-page":"130","article-title":"New Insights into antisynthetase syndrome","volume":"11","author":"Cojocaru","year":"2016","journal-title":"Maedica (Bucur)"},{"key":"10.1016\/j.ejim.2023.07.010_bib0006","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CPM.0000000000000171","article-title":"The diagnosis and treatment of antisynthetase syndrome","volume":"23","author":"Witt","year":"2016","journal-title":"Clin Pulm Med"},{"key":"10.1016\/j.ejim.2023.07.010_bib0007","doi-asserted-by":"crossref","first-page":"e27230","DOI":"10.1097\/MD.0000000000027230","article-title":"Association between clinical phenotypes of dermatomyositis and polymyositis with myositis-specific antibodies and overlap systemic autoimmune diseases","volume":"100","author":"Hui-Ling","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"10.1016\/j.ejim.2023.07.010_bib0008","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.ejim.2023.07.010_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"10.1016\/j.ejim.2023.07.010_bib0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4078\/jrd.2019.26.3.165","article-title":"The role of autoantibodies in idiopathic inflammatory myopathies","volume":"26","author":"Yoo","year":"2019","journal-title":"J Rheum Dis"},{"issue":"3","key":"10.1016\/j.ejim.2023.07.010_bib0011","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/03009742.2013.868512","article-title":"Canadian Scleroderma Research Group (CSRG)","volume":"43","author":"Jung","year":"2014","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"10.1016\/j.ejim.2023.07.010_bib0012","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/ard.62.8.728","article-title":"Risk of cancer in patients with scleroderma: a population based cohort study","volume":"62","author":"Hill","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ejim.2023.07.010_bib0013","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/2397198320905983","article-title":"Advances at the interface of cancer and systemic sclerosis","volume":"6","author":"Mecoli","year":"2021","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.ejim.2023.07.010_bib0014","doi-asserted-by":"crossref","DOI":"10.1007\/s12016-021-08911-z","article-title":"Anti-Ro52 autoantibody is common in systemic autoimmune rheumatic diseases and correlating with worse outcome when associated with interstitial lung disease in systemic sclerosis and autoimmune myositis","author":"Chan","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.ejim.2023.07.010_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106134","article-title":"Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis","volume":"172","author":"Xing","year":"2020","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.ejim.2023.07.010_bib0016","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","article-title":"Systemic sclerosis-associated interstitial lung disease","volume":"8","author":"Perelas","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.ejim.2023.07.010_bib0017","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","article-title":"EUSTAR collaborators. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database","volume":"80","author":"Hoffmann-Vold","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2023.07.010_bib0018","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1378\/chest.13-2626","article-title":"Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review","volume":"146","author":"Winstone","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2023.07.010_bib0019","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ejim.2023.07.010_bib0020","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1164\/rccm.200808-1359OC","article-title":"Gastroesophageal reflux and pulmonary fibrosis in scleroderma","volume":"179","author":"Savarino","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ejim.2023.07.010_bib0021","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3899\/jrheum.120705","article-title":"Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis","volume":"40","author":"Zhang","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2023.07.010_bib0022","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar3125","article-title":"Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort","volume":"12","author":"Assassi","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ejim.2023.07.010_bib0023","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.22099","article-title":"Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline","volume":"55","author":"Plastiras","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2023.07.010_bib0024","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/ard.62.2.146","article-title":"Predictors of end stage lung disease in a cohort of patients with scleroderma","volume":"62","author":"Morgan","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ejim.2023.07.010_bib0025","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1183\/09031936.00156312","article-title":"Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival","volume":"42","author":"Hervier","year":"2013","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ejim.2023.07.010_bib0026","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/24725625.2020.1794521","article-title":"Antisynthetase syndrome and pulmonary hypertension: report of two cases and review of the literature","volume":"5","author":"Garc\u00eda-Fern\u00e1ndez","year":"2021","journal-title":"Mod Rheumatol Case Rep"},{"key":"10.1016\/j.ejim.2023.07.010_bib0027","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020935289","article-title":"Anti-synthetase syndrome-associated pulmonary veno-occlusive disease","author":"Kay","year":"2020","journal-title":"Pulm Circ"},{"key":"10.1016\/j.ejim.2023.07.010_bib0028","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X211032457","article-title":"Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders","volume":"13","author":"Kuwana","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"5","key":"10.1016\/j.ejim.2023.07.010_bib0029","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02026-2019","article-title":"Predictors of progression in systemic sclerosis patients with interstitial lung disease","volume":"55","author":"Distler","year":"2020","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ejim.2023.07.010_bib0030","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1097\/RHU.0000000000001676","article-title":"Anti-polymyositis\/scl antibodies in systemic sclerosis: clinical associations in a multicentric Spanish cohort and review of the literature","volume":"28","author":"Iniesta Arandia","year":"2022","journal-title":"J Clin Rheumatol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523002352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523002352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:38:51Z","timestamp":1760607531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523002352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":30,"alternative-id":["S0953620523002352"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.07.010","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of anti-synthetase antibodies among systemic sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}